Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.

Name: Αlpha¹ Rigor Record — Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
Item: Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.
Rating: 96
Author: Αlpha¹

Mamounas EP, Bandos H, White JR, Julian TB, Khan AJ, Shaitelman SF, Torres MA, Vicini FA, Ganz PA, McCloskey SA, Lucas PC, Gupta N, Li XA, McCormick B, Smith B, Tendulkar RD, Kavadi VS, Matsumoto K, Seaward SA, Irvin WJ Jr, Lin JY, Mutter RW, Muanza TM, Stromberg J, Jagsi R, Weiss AC, Curran WJ Jr, Wolmark N

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 4.25★ (Strong), 0 critical, 5 high issues for “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

4.25 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported phase 3 randomized controlled trial with clear scientific premise, detailed methods, and appropriate statistical analysis. The main weaknesses are the absence of a data availability statement, lack of explicit statistical software identification, and minor reporting gaps (randomization method, blinding rationale, sex of participants).

Both reviewers independently scored all eight dimensions and agreed on all statuses; no divergence required reconciliation. The statistics verification recomputed 5 reported tests (all consistent) but coverage is limited to tests with test statistics/CI; other p-values were not machine-verified. The citation check found no retracted or unresolved references. The integrity check flagged an internal contradiction regarding the overall survival denominator (1,802 vs 1,641 enrolled), which is a reporting inconsistency to address.

6 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 1 recomputed directly from the reported test statistics, 4 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites multiple randomized trials and retrospective analyses establishing the benefit of regional nodal irradiation in node-positive patients and the prognostic significance of ypN0. It identifies the gap in evidence for patients converting to ypN0 after neoadjuvant chemotherapy. The rationale for the trial is clearly linked to this gap, and the limitations of prior retrospective studies are acknowledged.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior work on regional nodal irradiation and neoadjuvant chemotherapy, and provides a logical rationale for the trial.

Evidence

direct quote[Introduction, paragraphs 1-3]

“Adjuvant regional nodal irradiation has been shown to reduce the risk of locoregional recurrence, distant recurrence, and death from breast cancer among patients with early-stage breast cancer who undergo surgery first and have pathologically involved axillary lymph nodes.”